Precision automation is moving from biology to business

Moderna and Merck recently presented Phase 3 trial results for a personalised mRNA cancer vaccine, according to @tiffintech on TikTok. The study involved 1,137 melanoma patients and showed that combining the vaccine with Keytruda reduced the risk of cancer recurrence by 42%. This approach uses algorithms to identify up to 34 specific mutations within a single patient's tumour to customise the treatment.

Why it matters

This breakthrough proves that AI is moving from generating text to solving biological problems. We are seeing a shift where algorithms do not just assist humans but actually design specific, physical products. For businesses, the takeaway is the scale of complexity being managed. The ability to sequence a tumour and select 34 unique mutations requires a level of data processing that was impossible a decade ago. However, do not mistake this for a universal solution. The cost of manufacturing a unique product for every single patient is a massive logistical hurdle. If the production speed cannot match the rate of diagnosis, the technology remains a luxury. The real test is whether we can automate the manufacturing as effectively as we have automated the design.

What it changes in practice

For the small and mid-sized Swiss companies we work with, nothing changes on Monday. This is a medical breakthrough, not a shift in digital marketing or general business operations. You will not see these personalised manufacturing workflows appearing in your office tomorrow. The complexity of this biological automation is too specialised to trickle down into standard service industries immediately.

However, the underlying logic matters. We are watching the transition from general AI tools to highly specific, data-driven automation. The lesson for your business is about precision. If an algorithm can successfully navigate the unique mutations of a single human tumour, it proves that hyper-personalisation is no longer a theoretical concept. It is a technical reality that will eventually redefine how any high-value product is designed and delivered.

What we would do

We do not apply medical algorithms to your social media strategy. Instead, we look at the shift from broad audience segments to individualised data points. Most marketing still relies on large, imprecise groups, which is becoming an inefficient way to spend a budget. If you want to compete with larger players, you must move away from generic messaging and start using data to recognise the specific needs of a single user.

1. Data segmentation overhaulWe stop targeting broad demographics and start categorising users by their specific interactions and behaviours.
2. Content modularityWe build creative assets that can be rapidly assembled to suit different individual preferences.
3. Feedback loop integrationWe use real-time performance metrics to adjust the automation settings every week rather than every quarter.

Within twelve months, companies will stop grouping customers by age or location. This shift requires you to integrate real-time physiological and behavioural data into your core product logic. Mass demographics will become obsolete.